Click here for slides on this topic


Very low-density lipoprotein cholesterol (VLDL-C)

The fraction of circulatin cholesterol that is contained in VLDL particles.
The following content matched the glossary term: Very low-density lipoprotein cholesterol (VLDL-C)

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 9, 2012

Top

Daily coverage of American Diabetes Association 72nd Scientific Sessions  June 9, 2012

Results from the EASIE, EUREXA, TODAY, and Diabetes Prevention Program (DPP) trials; new data on SGLT2 inhibitors for diabetes treatment, incretins for diabetes treatment, ATP-IV guideline update, and more.

 

Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia

Top

Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, Khan MA, Perez AT, Tan MH. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007;30(10):2458-64. Associated with insulin resistance in type 2 diabetes are increased serum triglycerides, decreased HDL cholesterol, and a predominance of large VLDL, small LDL, and small HDL particles.

Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects

Top

Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care. 2007 Aug;30(8):1945-51. Epub 2007 May 4. OBJECTIVE: The aim of this study was to determine the effects of fenofibrate (160 mg/day) on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in subjects with hypertriglyceridemia and the metabolic syndrome.

Apolipoprotein E Kinetics: Influence of Insulin Resistance and Type 2 Diabetes

Top

Bach-Ngohou K, Ouguerram K, Nazih H, et al. Apolipoprotein E Kinetics: Influence of Insulin Resistance and Type 2 Diabetes. Int J Obesity. 2002;26:1451-1458. The aim of this study was to explore apoE kinetics of obese subjects and to determine what parameters could influence its metabolism.

Diabetes Contributes to Cholesterol Metabolism Regardless of Obesity

Top

Simonen PP, Gylling HK, Miettinen TA. Diabetes Contributes to Cholesterol Metabolism Regardless of Obesity. Diabetes Care. 2002;25:1511-1515. OBJECTIVE-To investigate cholesterol metabolism in obesity with and without diabetes.

Effect of Insulin and Sulfonylurea Therapy, at the Same Level of Blood Glucose Control, on Low Density Lipoprotein Subfractions

Top

Rivellese AA, Patti L, Romano G, et al. Effect of Insulin and Sulfonylurea Therapy, at the Same Level of Blood Glucose Control, on Low Density Lipoprotein Subfractions in Type 2 Diabetic Patients. J Clin Endocrinol Metab. 2000;85:4188-4192. The aim of this study was to evaluate the effect of sc insulin (INS) compared with sulfonylurea (SUL) therapy, at the same level of blood glucose control, on the low density lipoprotein (LDL) subfraction profile in normolipidemic type 2 diabetic patients.

VLDL Subfractions in Type 2 Diabetes

Top

McEneny J, O'Kane MJ, Moles KW, et al. Very low density lipoprotein subfractions in type II diabetes mellitus: alterations in composition and susceptibility to oxidation. Diabetologia. 2000;43:485-493. Type II (non-insulin-dependent) diabetes mellitus is associated with raised triglycerides and increased very low density lipoprotein cholesterol. The aim of this study was to assess if very low density lipoprotein subfraction composition and potential to oxidise were altered in this condition.

Relationship Between Insulin Resistance and Nonmodulating Hypertension Linkage of Metabolic Abnormalities and Cardiovascular Risk

Top

Ferri C, Bellini C, Desideri G, et al. Relationship Between Insulin Resistance and Nonmodulating Hypertension Linkage of Metabolic Abnormalities and Cardiovascular Risk. Diabetes. 1999;48:1623-1630. Insulin resistance is a feature common to patients with diabetes and to some with hypertension. It is assumed that this feature confers the increased metabolic risk in hypertension. However, the state of the renin-angiotensin system might contribute to cardiovascular risk, although there is no clear mechanistic explanation.

Apolipoprotein(B) Identifies Dyslipidemic Phenotypes Associated With Cardiovascular Risk in Normocholesterolemic Type 2 Diabetic Patients

Top

Wägner AM, Pérez A, Calvo F, Bonet R, Castellví A, Ordóñez J. Apolipoprotein(B) Identifies Dyslipidemic Phenotypes Associated With Cardiovascular Risk in Normocholesterolemic Type 2 Diabetic Patients. Diabetes Care. 1999;22:812-817. Apolipoprotein(B) [apo(B)] reflects the total mass of atherogenic particles (VLDL, IDL, and LDL), and its increase is associated with cardiovascular disease independently of LDL cholesterol (LDLc) levels.

Insulin Sensitivity in Subjects With Type 2 Diabetes Relationship to Cardiovascular Risk Factors: The Insulin Resistance Atherosclerosis Study

Top

Haffner SM, D"Agostino R Jr, Mykkänen L, et al. Insulin Sensitivity in Subjects With Type 2 Diabetes Relationship to Cardiovascular Risk Factors: The Insulin Resistance Atherosclerosis Study. Diabetes Care. 1999;22:562-568. Among nondiabetic subjects, insulin resistance has been associated with increased cardiovascular risk factors, including dyslipidemia, hypertension, impaired fibrinolysis, and coagulation. Less is known about the relationship between insulin resistance and cardiovascular risk factors in subjects with type 2 diabetes.

1 2 Next 

Slide Library Results

Search Results for: Very low-density lipoprotein cholesterol (VLDL-C) Slides Found: 0